Study Evaluating Etanercept and Methotrexate in Plaque Psoriasis

Wyeth is now a wholly owned subsidiary of Pfizer60 enrolled

Overview

The purpose of this study is to evaluate the efficacy to clear or almost clear the plaques in plaque psoriasis patients, treated with the combination etanercept and methotrexate compared to etanercept alone.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Psoriasis Arthritis, Psoriatic

Interventions

EtanerceptDRUG

MethotrexateDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Active plaque psoriasis involving \>10% body surface area and/or minimal screening PASI score 8. * Methotrexate \>7.5 mg/week for the last 3 months Exclusion Criteria: * Predominantly guttate, erythrodermic or pustular psoriasis * Other skin conditions than psoriasis

Locations (8)

Unnamed facility

Fredriksberg Alle, Copenhagen, Denmark

Unnamed facility

Gentofte Amtsygehus, Hellerup, Denmark

Unnamed facility

Helsinki, Helsinki, Finland

Unnamed facility

Tampere, Pirkanmaa, Finland

Outcomes

Primary Outcomes

Proportion of pts whose plaque psoriasis is cleared or almost cleared after 24 weeks.

Secondary Outcomes

Percentage improvement in PASI. Proportion of pts demonstrating PASI 50, 75

and 90. Time to clear or almost clear on PGA.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.